Latest Nasdaq News

Radiopharm Theranostics has received an $8 million advance against its anticipated FY26 Australian R&D tax incentive, giving the clinical-stage company additional funding for trials and working capital. The facility carries commercial interest and must be repaid by 26 October 2027.

European Lithium has secured Supreme Court approval for its proposed share and option schemes with Critical Metals Corp., removing the central legal hurdle to the transaction. The deal is now expected to move from ASX trading to a NASDAQ-listed CRML structure in early November, subject to the court orders being lodged with ASIC.

Immutep’s FY2026 filing puts the full cost of the failed TACTI-004 Phase III trial on display: a larger loss, an impaired efti asset and a manufacturing investigation that remains unresolved. The company has A$68.9 million in cash and term deposits, which it forecasts will fund operations into the first half of calendar 2028 under current plans.

Elevra Lithium has completed the sale of its Ghanaian Ewoyaa project interest to Zhejiang Huayou Cobalt for US$71 million in cash before fees and taxes. The deal removes its development funding obligations and transfers its spodumene offtake rights, leaving the company more focused on its North American portfolio.

Sunrise Energy Metals has completed key Syerston engineering work and received a conditional commitment for up to US$400 million in long-term debt from the U.S. Office of Strategic Capital. The project’s revised scope now carries an estimated A$450 million to A$475 million capital cost, while the proposed Nasdaq redomiciliation remains subject to multiple approvals.

Energy World has completed a major delivery milestone in its US$350 million turbine sale, receiving US$50 million and securing a further US$265 million in escrow. Most of the remaining proceeds still depend on inspection, refurbishment costs and final completion in early 2027.

European Lithium has completed the shareholder and optionholder meetings on Critical Metals Corp.’s proposed acquisition, but the verified poll results were not included in the announcement. Proxy votes showed overwhelming support for both schemes, leaving Court approval and final conditions as the next hurdles.

Starpharma has submitted its European trial application for DEP HER2-Lu and completed manufacture of clinical material, bringing its lead radiopharmaceutical closer to first patient dosing. The biotech also took control of Petalion, collected a Radiopharm option fee and finished the quarter with AUD $34.4 million in cash.

NOVONIX has made a second US$7 million amortisation payment under its convertible debenture funding agreement with Yorkville affiliate YA II PN, Ltd. The payment reduces the amount outstanding to US$21 million, but further cash demands may follow if the company’s share price remains below A$0.12.

MEC Resources ended the September quarter with $1.275 million in cash and reported an estimated 11.9 quarters of funding at its current operating cash burn. But its key Advent Energy investment faces a live Federal Court appeal over PEP11, while an onshore subsidiary holding the Weaber Gas Field remains in voluntary administration.

European Lithium has set the exchange ratio for its proposed merger with Critical Metals Corp. at 0.045 CRML shares for each EUR share, after CRML’s reference price fell at or below the deal’s US$8 floor. Securityholders vote on the schemes tomorrow, with court approval and other conditions still outstanding.

Telix reported US$245 million in unaudited third-quarter revenue, with Precision Medicine sales up 30% and full-year revenue and other income still expected to exceed US$1 billion. The quarter also advanced the proposed US$1.65 billion ITM merger, added FDA-approved Pixclara to the commercial portfolio and narrowed the R&D spending range.